Company Overview and News
THE MAIN INDEX clawed its way back above the 7,000 mark on Friday from Thursday’s worst year-to-date finish on bargain hunting and signs that Sino-US trade tensions could ease.
SVTMF NOW GTMEY SM AEV SECB SMIVY SSI JBFCF MWP PHSXY GTMEF PSE SPHXF MWIDE SPHZF GLOPA UVRBF AYAAF PSKXF AYAAY JBFCY UVRBY GLOPP SMPH GLO ABTZY SPHXY SYBJF JFC URC DNOW ALI
THE PHILIPPINE STOCK EXCHANGE index (PSEi) exited bear territory on Friday amid what one analyst described as “a dizzying rally”, but its strong recovery was not enough to prevent its third straight week-on-week drop.
FPHPC MPCIY BDOUY AYAAY UVRBY AEV FPHP DD SECB MRAIF BDOUF BDO ABTZY MPI MPCFF SYBJF URC MRC ALI FPH UVRBF AYAAF
ABOITIZ Power Corp. is in talks with two interested parties for the sale of the 8.8-megawatt (MW) biomass power plant in Lian, Batangas under subsidiary Aseagas Corp., which it wrote off for P3.7 billion in January this year.
ABZPF ABTZY ABZPY AEV AP
A CONSORTIUM led by the Ayala and Aboitiz groups will be shelling out P15 billion for its proposal to design and develop the infrastructure for the country’s national identification (ID) system.
(Sept 12): Southeast Asian stock markets ended on a cautious note on Wednesday, as broader Asian peers hit a 14-month low, amid worries of intensifying Sino-U.S. trade war, with Philippine shares extending losses to a sixth straight session.
ABTZY AEV O39
A consortium formed by seven of the country’s biggest conglomerates insisted on Wednesday that it was not seeking any government guarantees, the existence of which could jeopardize its offer to modernize and operate Manila’s Ninoy Aquino International Airport (Naia) for 15 years.
JGSMY JGS MPCIY AEV FILIY ALGGY ABTZY MPI MPCFF ALGGF FDC AGI JGSHF
SHARES SLUMPED on Wednesday as the local market paused for a break after rallying past the 7,800 level in previous days.
GTCAP GTCXY SMCP1 RBNTF AEV SMGBF SMC MPCFF RRETY PHSXY PSE RRHI PSKXF MPCIY SMGBY SMC2B SMC2A SMC2D SMC2C ABTZY MPI SMC2F SMC2E BBRRF BLOOM
AUTHORITIES will start a pilot run to register residents under the Philippine ID System (PhilSys) in December, as they look to start with households receiving cash transfers from government.
THE implementing agency for the Philippine Identification System Act said it is preparing the terms to auction the design contract for the infrastructure underlying the national identification (ID) system.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...